BioLineRx Ltd. (BLRX) BioLineRx Ltd., an Israeli biopharmaceutical firm established in 2003 and based in Hevel Modi'in, focuses its clinical-stage development efforts primarily on oncology. Their leading investigational product, Motixafortide, a peptide, has successfully concluded pivotal Phase 3 clinical trials for mobilizing stem cells in autologous transplants, and Phase 2a trials targeting pancreatic cancer. This compound is currently progressing through Phase 2 studies for metastatic pancreatic adenocarcinoma and Phase 1b trials for acute respiratory distress syndrome linked to COVID-19 and other viral infections. Additionally, Motixafortide is being investigated for its therapeutic potential in solid tumors and acute myeloid leukemia. The company's pipeline also includes AGI-134, an immuno-oncology agent presently undergoing Phase 1/2a clinical evaluations for various solid tumors. Furthermore, BioLineRx is advancing BL-5010, a custom-designed, proprietary pen-like device intended for the non-surgical removal of skin lesions. BioLineRx maintains strategic alliances, notably a collaboration with MSD in the domain of cancer immunotherapy, and an agreement with MD Anderson Cancer Center to explore Motixafortide combined with KEYTRUDA (pembrolizumab) for pancreatic cancer. They also have a licensing deal with Perrigo Company plc for the over-the-counter sale of BL-5010.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
BioLineRx Ltd. NASDAQ:BLRX Healthcare · Biotechnology
Mkt Cap $5.58M
EV -
SI 2.8%
Net Cash/Sh -
CLOSED · Nov 17 -2.61%$1.12 CLOSED · Nov 17 Prev close $1.15 -2.61%Close $1.12 0.00% AH close $1.12 VOL 33K $ Vol $40K RVOL 2.98x
Mkt Cap $5.58M
EV -
VOL 33K sh
$ Vol $40K
RVOL 2.98×
SI 2.8%
Net Cash/Sh -
Press Release
BioLineRx and Hemispherian Present Phase 1/2a Clinical Study and Pre-Clinical Updates, Including Brain PK/PD Data, at SNO 2026
BioLineRx and Hemispherian presented two posters on GLIX1, a first-in-class oral TET2 activator, at the 31st Society for Neuro-Oncology Annual Meeting. The Phase 1/2a study in high-grade glioma has initiated its fourth cohort with no significant treatment-emergent adverse events, and remaining cohorts will add a window-of-opportunity setting to directly assess brain penetration in human tumor tissue. Preclinical data showed robust, dose-dependent antitumor activity across multiple GBM models, including tumor eradication in the SNB19 model and growth inhibition in a TMZ-resistant PDX where TMZ failed, with confirmed brain penetration and dose-dependent 5hmC increases.
• 1d ago AI analysis › Press Release
BioLineRx and Hemispherian Present Preclinical Data Demonstrating Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancer at ESMO 2026
BioLineRx and Hemispherian presented preclinical data at ESMO 2026 showing GLIX1 synergizes with three PARP inhibitors (olaparib, veliparib, niraparib) in HR-proficient ovarian cancer models, with ZIP synergy scores of 10.9-43.2. In a patient-derived xenograft model, a low-dose GLIX1 plus olaparib combination produced statistically significant tumor growth inhibition comparable to cisplatin, outperforming either agent alone at optimal doses.
• 25d ago AI analysis › Press Release
BioLineRx and Hemispherian Announce Two GLIX1 Presentations at the 31st Society for Neuro-Oncology (SNO) Annual Meeting & Education Day
BioLineRx and partner Hemispherian announced two poster presentations on GLIX1 at the 31st Society for Neuro-Oncology Annual Meeting, November 12-15 in Philadelphia. One poster covers preclinical anti-tumor activity across multiple glioblastoma models, including a TMZ-resistant PDX model; the other outlines the ongoing Phase 1/2a trial in recurrent or progressive high-grade glioma and other solid tumors.
• 1mo ago AI analysis › Press Release
BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026)
BioLineRx and its German-partner collaborator Hemispherian AS will present two accepted GLIX1 abstracts at EANO 2026 in Rome (September 24-27), including a mini-oral highlighting preclinical efficacy in orthotopic glioblastoma models. The preclinical package shows dose-dependent tumor growth inhibition and survival benefit across two orthotopic GBM xenograft models plus a temozolomide-resistant patient-derived xenograft, with brain exposures at 68-85% of plasma levels supporting CNS penetration.
• 2mo ago AI analysis › Press Release
BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update
BioLineRx reported Q2 2026 revenue of $0.3 million with a net loss of $4.3 million, ending the quarter with $13.1 million in cash to fund operations into the first half of 2027. The company announced positive preclinical data for its lead asset GLIX1, showing potent antitumor activity in TMZ-resistant glioblastoma models and strong synergy with PARP inhibitors in ovarian cancer models. Management is advancing the Phase 1/2a GBM trial, with the second cohort dosing and the third expected to start in September, while simultaneously planning an ovarian cancer arm for the Phase 2a expansion.
• 2mo ago AI analysis › Press Release
BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement
BioLineRx priced a $3.75 million registered direct offering and concurrent private placement, selling approximately 1.35 million ADSs at $2.78 per share. The transaction includes warrants to purchase up to 2.02 million ADSs and an amendment to existing warrants covering 277,273 ADSs, which lowers the exercise price to $2.78 and extends the expiration date to August 31, 2031.
• 2mo ago AI analysis › Press Release
BioLineRx to Report Second Quarter 2026 Results on August 31, 2026
BioLineRx announced it will release its unaudited financial results for the second quarter ended June 30, 2026 on August 31, 2026, before U.S. markets open. Management will host a conference call at 8:30 a.m. ET featuring remarks from CEO Philip Serlin to discuss the results.
• 2mo ago AI analysis › Press Release
BioLineRx and Hemispherian AS to Present Data Demonstrating Strong Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancers at ESMO 2026
BioLineRx and partner Hemispherian AS announced that an abstract featuring pre-clinical data demonstrating strong synergy between GLIX1 and PARP inhibitors in HR-proficient ovarian cancers was accepted for presentation at ESMO 2026. The data addresses a significant unmet need, as PARP inhibitors are currently markedly less effective in the approximately 50% of patients with HR-proficient tumors who often exhibit primary platinum resistance.
• 3mo ago AI analysis › Press Release
BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model
BioLineRx and partner Hemispherian announced positive preclinical data demonstrating strong synergy between GLIX1 and the PARP inhibitor olaparib in a patient-derived ovarian cancer model. The combination therapy showed tumor reduction comparable to the chemotherapy benchmark cisplatin and outperformed monotherapy arms, supporting the synthetic lethality mechanism in HR-proficient tumors.
• 4mo ago AI analysis › Press Release
BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update
BioLineRx reported Q1 2026 revenue of $0.5 million, driven by royalties from APHEXDA sales, and a net loss of $2.6 million. The company highlighted a key milestone: the first patient was dosed in the Phase 1/2a clinical trial for GLIX1 in glioblastoma, with two additional abstracts accepted for ASCO.
• 5mo ago AI analysis › Press Release
BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
BioLineRx and partner Hemispherian AS are presenting two abstracts on GLIX1 at the ASCO 2026 Annual Meeting, highlighting preclinical data and early clinical progress. The first abstract details GLIX1's novel mechanism as a TET2 activator that induces tumor-selective DNA damage, showing strong antitumor activity in glioblastoma models and efficient brain penetration (68-85% of plasma levels). The second abstract demonstrates synergistic antitumor activity when combining GLIX1 with PARP inhibitors across multiple cancer types, providing a rationale for future combination trials.
• 5mo ago AI analysis › Press Release
BioLineRx to Report First Quarter 2026 Results on May 27, 2026
BioLineRx will report unaudited Q1 2026 financial results on May 27, 2026, before U.S. market open. CEO Philip Serlin will host a conference call at 8:30 a.m. EDT to discuss the results.
• 5mo ago AI analysis › Press Release ● Major
BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Patient-Derived Xenografts
prnewswire.com • 5mo ago Press Release
BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)
BioLineRx and partner Hemispherian dosed the first patient in a Phase 1/2a study of GLIX1 for recurrent and progressive glioblastoma. The first-in-human trial will enroll up to 30 patients to establish safety and dosing, with Phase 1 data anticipated in the first half of 2027.
• 6mo ago AI analysis › Press Release ● Major
Hemispherian Initiates Phase 1/2a Clinical Trial of GLIX1 in Glioblastoma
businesswire.com • 7mo ago Press Release
BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)
prnewswire.com • 7mo ago Press Release ● Major
BioLineRx Reports 2025 Financial Results and Provides Corporate Update
prnewswire.com • 7mo ago Press Release ● Major
BioLineRx to Report 2025 Annual Results on March 23, 2026
prnewswire.com • 8mo ago